[A comparative study of thio-tepa and mitomycin C in the treatment of pterygium. Preliminary results].
OBJECTIVE
To compare the efficacy of Thio-tepa and Mitomycine C to obviate recurrence; to compare cost-efficacy ratios; to evaluate their facility of use and their complications.


METHODS
In a prospective blinded study, 36 patients undergoing surgery for 46 primary and recurrent pterygium were assigned randomly to three groups: group 1 received 0.02 mg/ml of Mitomycine C three times daily for 5 days; group 2 received Thio-tepa four times daily for 6 weeks, group 3 served as a control receiving distilled water three times daily for five days.


RESULTS
Recurrence rates were 38%, in group 1; 28% in group 2; 82% in group 3 respectively. Follow-up ranged from 15 to 44 weeks (mean 27.93 +/- 8.9 weeks). Mean delay recurrence time was 6.3 weeks. Topical Mitomycin caused: iritis, conjunctival irritation, excessive lacrymation, photophobia, ocular pain; Thio-tepa caused: photophobia, foreign body sensation, headache.


CONCLUSIONS
Mitomycine C appears to be an effective and safe adjunctive treatment for this cost-efficacy and this facility of use comparison.
Service d'Ophtalmologie, Cliniques Universitaires, Université de Kinshasa, République Démocratique du Congo.
D
D
Ngoy
L
L
Kayembe
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003228:Conjunctiva / Q000187:drug effects; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007500:Iritis / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D019384:Nucleic Acid Synthesis Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011446:Prospective Studies; D011625:Pterygium / Q000188:drug therapy*; D011680:Pupil / Q000187:drug effects; D012008:Recurrence; D012449:Safety; D016037:Single-Blind Method; D013666:Tears / Q000187:drug effects / Q000378:metabolism; D013852:Thiotepa / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
D000477:Alkylating Agents; D019384:Nucleic Acid Synthesis Inhibitors; D016685:Mitomycin; D013852:Thiotepa
Etude comparative du Thio-tepa et de la Mitomycine C dans le traitement du ptérygion. Résultats préliminaires.